Alpha PRRT with Pb-212 VMT

Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)

IDENTIFIER (ClinicalTrials.gov): NCT05636618

DRUG/TREATMENT: Alpha PRRT with 212Pb VMT

PHASE: 1 / 2A

STATUS: Recruiting

SPONSOR: Perspective Therapeutics

DESCRIPTION:

June 2024: Dr. Aman Chauhan discusses the Alpha PRRT with Pb-212 VMT study.

Perspective Therapeutics is sponsoring a phase 1 / 2A prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT01 in up to 52 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT).

During phase 1, there is a dose escalation period testing up to 4 escalating radioactivity dose cohorts of up to 8 subjects (administered at approximately 8-week intervals) at the assigned cohort radioactivity dose. Phase 1 studies the side effects, safety, and dosimetry.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

Markus Puhlmann, MD, MBA at Perspective Therapeutics

EMAIL: mpuhlmann@perspectivetherapeutics.com

PHONE: (319) 665-2150